Luminopia Inc. reeled in $16 million in an oversubscribed series A financing led by U.S. Venture Partners. The funds will support full commercial launch of the company’s U.S. FDA-cleared digital therapeutic for the treatment of children ages 4-7 with amblyopia. “We are thrilled to announce the successful close of our oversubscribed series A round, which will allow us to advance our mission of pioneering a new class of treatments for the 15 million Americans who suffer from neuro-visual disorders,” said Scott Xiao, Luminopia’s co-founder and CEO.
Vesalius Biocapital Partners Sàrl has called a first close on its fourth fund at €95 million (US$103 million) and now is targeting a total of €150 million, with new investors to be accepted on a "rolling closing" basis until the final close in 2024.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Candela, Cresilon, Zap Surgical.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amplitude Surgical, Avanos, Changzhou Zhongjin Medical Equipment, Dermtech, Elios, Enovis, Integra, Intelligent Bio Solutions, Novastep, Shanghai Sdoma Smart Technology.
Sometimes a merger or acquisition brings a device that has a set of indications for use that cannot be practicably expanded, but Nathan Downing of Gardner Law of Stillwater, Minn., said this is not always the case. Downing said that preliminary conversations between the two parties to mergers and acquisitions can clarify a lot about whether a particular device has ample room to grow.
Isotope Technologies Munich SE (ITM) raised $280 million to support the expansion of its broad targeted radionuclide therapies oncology pipeline. This equity investment round was led by Temasek holdings Pte Ltd. with participation from Blackrock Alternatives, Qatar Investment Authority, Nextech Invest Ltd., Athos KG and Carbyne Equity Partners GmbH.
Israeli venture capital fund, Shoni Health Ventures, launched a new fund focused on startups specializing in digital health and medical devices. Recognizing that innovative solutions with the potential to improve global health may go unrealized as health tech startups struggle to attract early-stage investors, the fund is focused on investing in companies at the pre-seed and seed-stage.
RSS
